Research Affiliates CEO on Leading and Investing in a Time of Uncertainty

By Dave Hendrick

Newswise — As CEO of global asset management firm Research AffiliatesKatrina Sherrerd (Ph.D. ’87) is leading the influential financial services firm through a period of deep global uncertainty, as world financial markets continue to show great volatility amid the coronavirus pandemic.

Sherrerd, who was named one of Barron’s 100 Most Influential Woman in Finance in 2020, says the firm’s investment beliefs and long-term trends serve as guides for Research Affiliates, which produces research and offers innovative investment products, many with a value investing focus.

At the close of the first quarter of 2020, more than $145 billion in assets were managed worldwide using investment strategies developed by the company.

Sherrerd, who holds an undergraduate degree from the University of Virginia McIntire School of Commerce and has taught at both Darden and McIntire, recently spoke about leading through crisis; environmental, social and governance (ESG) investing; and the value of diversity of thought.

The smart beta strategy pioneered by Research Affiliates has been described as essentially a passive investing strategy tweaked to generate above market returns. Is that fair?

Yes, but I would describe it a little bit differently. We produce rules-based, transparent investment strategies that are intended to beat the cap-weighted benchmark. We could have created a rules-based strategy in a black box — as many other firms do — and charge more, but we chose to deliver the strategy via an index construct for the benefit of investors.

The real question is whether our strategies are passive. If you believe passive means you are not making any decisions or taking active bets, then our smart beta strategies are active, because we are making active bets against the cap-weighted benchmark. If you believe passive means you deliver your strategy via an index, well then our smart beta strategies are passive. The term “passive” is not clear and, to be provocative, some people at Research Affiliates consider cap-weight to be an investment strategy delivered via index because they involve decisions on both constituents and weighting.

We also offer active strategies. Our active strategies are research and rules-based, but they are not as transparent as our RAFI strategies.

You told a Darden class recently that you were skeptical of your own ability to pick stocks. How do you come about that humility with regard to investing?

There are two aspects of it. First, I think stock picking is extraordinarily difficult. Some people are really skilled at it and others aren’t. Stock picking involves making buy and sell decisions using, for the most part, backward-looking data and management-filtered information. Skilled stock pickers tend to dig deep, and they’ve got a good sense for what’s said and what’s unsaid. They commit to gathering the necessary information and have the skill to synthesize it effectively. I am not that type of person. I’m not going to invest the time to become expert enough to have competence in making individual stock picks.

Second, I don’t like making bets on a few companies that I think will outperform the market. I’m much more comfortable diversifying across a larger number of securities in a systematic way that doesn’t leave me overly exposed to any one company or my own biases. I am also much more comfortable letting an expert do the hard work of selecting, weighting and — importantly — rebalancing the companies in a strategy, like a smart beta strategy such as a RAFI index.

How are you and your colleagues thinking about equity markets and getting your arms around the scale of what has happened to the global economy amid the coronavirus pandemic this spring?

It’s really difficult because there’s huge uncertainty and it’s very different from other crises. You can’t compare it to the tech bubble or the great financial crisis. It’s different, and it’s unclear what the future will look like.

Our general practice is to rely on research and long-term historical relationships to guide us. In times of uncertainty like this, we can’t tell you with much certainty whether value stocks will outperform growth stocks in the next 12 months. We have much more confidence saying that value stocks will outperform growth stocks within a couple years. Our analysis shows that the difference between the pricing for the average value stock versus the pricing for the average momentum stock is at its widest ever. We’ve passed the Depression-era delta between the two. We think the current relationship is not sustainable.

How do you think about ESG investing in the current environment?

The trend was growing pretty rapidly before 2020, and people often point to millennials investing as leading to demand for protecting the environment and being socially responsible, by various definitions. I think that trend will continue, regardless of the current pandemic. If anything, the pandemic is highlighting cases where governance, social and environmental practices are falling short. We are seeing, for example, which companies offer health and sick leave benefits — and which ones don’t.  This may not be important to all investors, but it certainly is important to many. We believe investor preferences are broader than simply risk and return. Many investors have environmental and social preferences, as well, and they should have the right to reflect their preferences in their investment decisions. This will lead to more ESG investing — assuming there are good Investment options.

Also, the increased transparency and dialog about ESG will, I believe, lead many companies to address perceived ESG deficiencies.

You are passionate about cultivating diversity of opinion in an organization. How do you seek to cultivate that?

Culture is important to me, and it is a distinguishing feature of Research Affiliates. An important part of our culture is our belief in collective intelligence, and the idea that a cognitively diverse group of individuals will make better decisions — particularly with difficult decisions and lots of uncertainty —than the smartest person in the group alone. With a team of very intelligent people, you can imagine that the leadership team must be totally committed to the benefits of our culture if we are going to succeed.

In building our culture, we seek to create an environment of curiosity, trust and respect for others. Building and maintaining the culture involves living our values, taking steps to promote the desired behaviors and minimize the undesired behaviors. I find describing the undesired behaviors can be more effective than the desired behaviors. For example, blame versus taking responsibility or putting a personal agenda ahead of a team objective. People tend to see the difference when the options are so stark.

We have a number of specific things that we do internally to make sure that we are being respectful of the different points of view and being curious about what people have to say. For example, we take steps to go around the room and make sure we hear from everybody. We discourage people from dominating conversations and the meeting leaders are expected to cut people off if they start dominating.

You have recently written about leadership in an age of uncertainty. How are you thinking about leading your team right now?

For starters, we’ve initiated more firm-wide communications than we had before. Zoom is helpful, but it doesn’t replace in-person conversations.

Also, I’m a big believer that we need to spend more time reaching out to the team now, because of the heightened uncertainty and anxiety. When people are anxious, they tend to want more guidance and assurance that they are making the “right” decisions in the face of significant uncertainty. To manage this, our leadership team needs to provide more guidance and increase communication. No one wants to be out of step with the direction of the firm and things that seem manageable in an office become much bigger issues when you’re sitting by yourself at home.

So we are proactively reaching out. We’ve instituted regular weekly meetings with all employees. We have weekly management meetings, where before they were monthly. I send out notes to people; other people are sending out notes regularly to try to engage people and give direction.

And we’re trying to find ways to show people that life is continuing on as normally as possible in these uncertain times. We have a saying at the company that to effectively communicate a message, you need to do more than have one person just say it. You also need to show people with multiple voices and visual images. So if you’re telling people that you’re aligned about something, you need to show people that you’re aligned. Thus, in the current environment, we have lots of voices expressing the important messages via Zoom, so we — the leadership team — can say and show at the same time.

About the University of Virginia Darden School of Business

The University of Virginia Darden School of Business delivers the world’s best business education experience to prepare entrepreneurial, global and responsible leaders through its MBA, Ph.D., MSBA and Executive Education programs. Darden’s top-ranked faculty is renowned for teaching excellence and advances practical business knowledge through research. Darden was established in 1955 at the University of Virginia, a top public university founded by Thomas Jefferson in 1819 in Charlottesville, Virginia.




Filters close

Showing results

1120 of 4578
Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Released: 15-Jan-2021 11:20 AM EST
Will Covid-19 kill the high street once and for all?
University of Sheffield

The shift to home working during Covid-19, or ‘Zoomshock’, threatens the survival of local goods and services provided in city centres and business parks

14-Jan-2021 5:00 PM EST
AACI Partners With Federal Vaccine Panel to Promote Cancer Patient Health
Association of American Cancer Institutes (AACI)

AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.

Released: 15-Jan-2021 8:55 AM EST
The First Dose of the Pfizer Vaccine Gives About 50% COVID Protection, Not 91% Claimed by Those Who Want to Speed Up Immunization
Newswise

The NEJM paper actually states that the efficacy between the first and second doses was found to be 52 percent when given 21 days apart. After the second dose, the efficacy raises to 95 percent.

Released: 15-Jan-2021 8:20 AM EST
Houston Methodist study finds males of all ages more affected by COVID-19 than females
Houston Methodist

A new Houston Methodist study found males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age. The peer-reviewed observational study appears in PLOS ONE, a multidisciplinary journal published by the Public Library of Science.

Released: 15-Jan-2021 8:20 AM EST
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Ivermectin is Now a Therapeutic Option for Doctors & Prescribers


Showing results

1120 of 4578

close
1.14225